DSM Capital Partners LLC Increases Holdings in Stryker Co. (NYSE:SYK)

DSM Capital Partners LLC grew its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 358.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,289 shares of the medical technology company's stock after buying an additional 2,572 shares during the period. DSM Capital Partners LLC's holdings in Stryker were worth $1,184,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. State Street Corp boosted its holdings in Stryker by 2.2% during the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock worth $5,279,788,000 after buying an additional 316,404 shares during the last quarter. FMR LLC boosted its holdings in Stryker by 3.0% during the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company's stock worth $2,639,725,000 after buying an additional 215,782 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Stryker by 2.5% during the third quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company's stock worth $2,484,893,000 after buying an additional 165,490 shares during the last quarter. Parnassus Investments LLC bought a new position in Stryker during the third quarter worth about $762,798,000. Finally, Janus Henderson Group PLC boosted its holdings in Stryker by 1.5% during the third quarter. Janus Henderson Group PLC now owns 1,969,757 shares of the medical technology company's stock worth $711,594,000 after buying an additional 28,421 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. StockNews.com cut Stryker from a "buy" rating to a "hold" rating in a report on Thursday, January 30th. BTIG Research raised their price target on Stryker from $383.00 to $394.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Evercore ISI raised their price target on Stryker from $380.00 to $384.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research report on Tuesday. Finally, Canaccord Genuity Group raised their price target on Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $420.68.

Insider Activity

In related news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Trading Down 1.0 %

Shares of NYSE SYK traded down $3.82 during trading on Friday, reaching $382.59. The company had a trading volume of 1,268,413 shares, compared to its average volume of 1,388,856. The company's fifty day moving average price is $378.07 and its 200-day moving average price is $368.67. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The stock has a market cap of $145.99 billion, a P/E ratio of 49.30, a PEG ratio of 2.93 and a beta of 0.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the company earned $3.46 earnings per share. As a group, research analysts expect that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker's dividend payout ratio is currently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.